Johnson & Johnson Pharmaceutical Research & Development L.L.C., 1000 Route 202, PO Box 300, Raritan, NJ 08869, USA. Ronghui.Lin@yahoo.com
Abstract:
A series of 3,5-disubstituted pyrazolo3,4-b]pyridine cyclin-dependent kinase (CDK) inhibitors was synthesized. These compounds showed potent and selective CDK inhibitory activities and inhibited in vitro cellular proliferation in cultured human tumor cells. Selected compounds were evaluated in an in vivo tumor xenograft model. The synthesis and biological evaluation of these pyrazolo3,4-b]pyridines and related compounds are reported.